Table 1.
Patient Characteristics
| No. of patients | % | |
|---|---|---|
| No. | 38 | |
| Age, years | ||
| Median | 53 | |
| Range | 30–69 | |
| Performance statusa | ||
| 0 | 31 | 81.6 |
| 1 | 5 | 13.2 |
| 2 | 2 | 5.3 |
| Menopausal status | ||
| Premenopause | 12 | 31.6 |
| Postmenopause | 26 | 68.4 |
| Receptor status | ||
| Estrogen receptor | ||
| Positive | 7 | 18.4 |
| Negative | 31 | 81.6 |
| Progesterone receptor | ||
| Positive | 6 | 15.8 |
| Negative | 31 | 81.6 |
| Unknown | 1 | 2.6 |
| Resistance to previous chemotherapies (Anthracycline/Taxane) | ||
| Primary resistance/Primary resistance | 7 | 18.4 |
| Primary resistance/Secondary resistance | 11 | 29.0 |
| Secondary resistance/Primary resistance | 6 | 15.8 |
| Secondary resistance/Secondary resistance | 11 | 29.0 |
| Unknown | 3 | 7.9 |
| Prior trastuzumab | ||
| Yes | 30 | 78.9 |
| No | 8 | 21.2 |
| Histology | ||
| Invasive ductal carcinomas | 34 | 89.5 |
| Other | 3 | 7.9 |
| Unknown | 1 | 2.6 |
| Number of metastasis | ||
| 1 | 27 | 71.1 |
| ≥2 | 10 | 26.3 |
| Unknown | 1 | 2.6 |
| Primary metastatic sites | ||
| Lung | 17 | 44.7 |
| Liver | 10 | 26.3 |
| Bone | 5 | 13.2 |
| Skin | 2 | 5.3 |
| Peritoneum | 1 | 2.6 |
| Mediastinum | 1 | 2.6 |
| Pleura | 1 | 2.6 |
| Unknown | 1 | 2.6 |
aEastern Cooperative Oncology Group